Aggressive Lymphomas
News
Sandoz won’t seek U.S. approval for rituximab biosimilar
Sandoz has decided not to pursue U.S. approval for its rituximab product (GP2013), a proposed biosimiliar of Rituxan/Mabthera. GP2013 (Rixathon,...
From the Journals
Novel risk factors for febrile neutropenia in NHL, solid tumors
Corticosteroid use was most strongly associated with chemotherapy-induced febrile neutropenia.
News
EC approves venetoclax in combo with rituximab
The European Commission (EC) has approved a new indication for venetoclax (Venclyxto®). The drug is now approved for use in combination with...
News
Novel risk factors for febrile neutropenia in NHL, other cancers
A retrospective study has revealed new potential risk factors for chemotherapy-induced febrile neutropenia (FN) in patients with solid tumors and...
From the Journals
Checkpoint inhibitor plus rituximab is active in non-Hodgkin lymphoma
Mainly low-grade toxic effects were seen on treatment with Hu5F9-G4 and rituximab in the study of relapsed and refractory patients.
From the Journals
Line complications plague dose-adjusted EPOCH-R in non-Hodgkin lymphoma
The risk of line-associated complications was significantly higher with dose-adjusted EPOCH-R therapy, compared with R-CHOP, in patients with...
From the Journals
First-line bortezomib prolongs survival in MCL
The survival benefits are promising with the addition of bortezomib, but there was no significant difference among high-risk patients.
News
Combo can prolong overall survival in MCL
Final results of a phase 3 trial suggest bortezomib plus rituximab and chemotherapy can significantly improve overall survival (OS) in transplant-...
From the Journals
Older age predicts mortality after alloHCT in NHL, but not relapse
The researchers said older age was an independent risk factor for nonrelapse mortality.
Conference Coverage
When to choose stem cell transplant in PTCL
DUBROVNIK, CROATIA – Dr. Ali Bazarbachi gives his tips for when to use allo- versus auto-HSCT in patients with peripheral T-cell lymphomas.
From the Journals
Study challenges LVEF assessment before DLBCL treatment
Preliminary findings have researchers questioning why cardiac testing is routine before administering chemotherapy containing doxorubicin.